Epicrispr Biotechnologies
Epicrispr Biotechnologies62About
What does Epicrispr Biotechnologies do?
Epicrispr Biotechnologies is a clinical-stage biotechnology company pioneering gene-modulating therapies. They are focused on developing a new class of programmable epigenetic medicines designed to durably regulate gene expression without permanently altering the underlying DNA sequence. Their lead program, EPI-321, is in clinical trials for Facioscapulohumeral Muscular Dystrophy (FSHD).
Is Epicrispr Biotechnologies trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Epicrispr Biotechnologies is 52 out of 100, based on site security posture and privacy practices.
What is Epicrispr Biotechnologies's revenue?
StartupHub estimates Epicrispr Biotechnologies's annual revenue at $5.9M (range $3.1M to $18.0M, 69% confidence), based on comparable companies in the sector.
What is Epicrispr Biotechnologies's valuation?
StartupHub estimates Epicrispr Biotechnologies's effective valuation at $381.6M (range $225.0M to $540.0M, 25% confidence), based on comparable companies in the sector.
How much funding has Epicrispr Biotechnologies raised?
Epicrispr Biotechnologies has raised a total of $90M in funding. The most recent round on record is Series C.
Where is Epicrispr Biotechnologies headquartered?
Epicrispr Biotechnologies is headquartered in South San Francisco, United States.
When was Epicrispr Biotechnologies founded?
Epicrispr Biotechnologies was founded in 2020.
What industry does Epicrispr Biotechnologies operate in?
Epicrispr Biotechnologies operates in Biotechnology, Therapeutics, Rare Diseases, Epigenetics, Biotech, MedTech.
How many employees does Epicrispr Biotechnologies have?
Epicrispr Biotechnologies has approximately 51 people on record.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
A company focused on privacy, Zcash accumulation, and developing cancer therapeutics.
Biotechnology startup developing next-generation cancer immunotherapies targeting shared tumor-associated antigens.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.